Information Provided By: 
Fly News Breaks for June 3, 2019
CTMX
Jun 3, 2019 | 07:07 EDT
Cantor Fitzgerald analyst Varun Kumar raised his price target for CytomX Therapeutics to $23 from $21 based on the CX-072 update provided this weekend at the ASCO annual meeting. The company reported "promising" single-agent clinical activity in triple-negative breast cancer patients, which looks overall favorable to historical single-agent anti-PDL1 agents, Kumar tells investors in a research note. He sees an attractive risk/reward for shares of CytomX and reiterates an Overweight rating on the name.
News For CTMX From the Last 2 Days
